Advertisement

Comparison of pregnancy rates in users of extended and cyclic combined oral contraceptive (COC) regimens in the United States: a brief report

      Abstract

      Objective

      To evaluate pregnancy rates with 84/7, 21/7, and 24/4 combined oral contraceptives (COCs).

      Study design

      Data were obtained from the i3Invision Data MartTM retrospective claims database. Subjects were 15 to 40 years; first prescribed COCs between January 1, 2006 and April 1, 2011; and continuously insured for ≥1 year. Eighty four over seven users (84/7) were matched 1:1 to 21/7 and 24/4 users.

      Results

      One-year pregnancy rates were significantly lower with 84/7 than with 21/7 (4.4% vs. 7.3%; p<.0001) and 24/4 (4.4% vs. 6.9%, p<.0001) regimens.

      Conclusion

      Preliminary results suggest fewer pregnancies with 84/7 versus 21/7 or 24/4 regimens.

      Implications

      While newer COCs, including 84/7 and 24/4 regimens, potentially improve efficacy and alter bleeding profiles compared to 21/7 regimens, few data on comparative pregnancy rates with these regimens are available. In this retrospective claims analysis, real-world pregnancy rates were lower with 84/7 regimens versus 21/7 and 24/4 regimens.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaunitz A.M.
        • Portman D.J.
        • Hait H.
        • Reape K.Z.
        Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
        Contraception. 2009; 79: 350-355
        • Vandever M.A.
        • Kuehl T.J.
        • Sulak P.J.
        • et al.
        Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
        Contraception. 2008; 77: 162-170
        • Anderson F.D.
        • Hait H.
        A multicenter, randomized study of an extended cycle oral contraceptive.
        Contraception. 2003; 68: 89-96
        • Klipping C.
        • Duijkers I.
        • Trummer D.
        • Marr J.
        Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
        Contraception. 2008; 78: 16-25
        • Reape K.Z.
        • DiLiberti C.E.
        • Hendy C.H.
        • Volpe E.J.
        Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive.
        Contraception. 2008; 77: 34-39
        • Fels H.
        • Steward R.
        • Melamed A.
        • Granat A.
        • Stanczyk F.Z.
        • Mishell Jr., D.R.
        Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.
        Contraception. 2013; 87: 732-737
        • Trussell J.
        • Portman D.
        The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?.
        Contraception. 2013; 88: 604-610
        • Dinger J.
        • Minh T.D.
        • Buttmann N.
        • Bardenheuer K.
        Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.
        Obstet Gynecol. 2011; 117: 33-40
        • Baerwald A.R.
        • Olatunbosun O.A.
        • Pierson R.A.
        Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use.
        Contraception. 2004; 70: 371-377
        • Jones R.K.
        • Upadhyay U.D.
        • Weitz T.A.
        At what cost? Payment for abortion care by U.S. women.
        Womens Health Issues. 2013; 23: e173-e178